ENTPD1 and melanoma: In melanoma, a high percentage of CD39+ TRMs is associated with better recurrence-free survival, and TRM-deficient mice are more susceptible to melanoma [63]; however, TRMs are increased in progressive cSCC [64], indicating tumor-specific differences in TRM roles.